1018 related articles for article (PubMed ID: 25444819)
1. Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.
Singh S; Yang G; Byrareddy SN; Barry MA; Sastry KJ
Vaccine; 2014 Dec; 32(51):6934-6940. PubMed ID: 25444819
[TBL] [Abstract][Full Text] [Related]
2. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.
Jiang JQ; Patrick A; Moss RB; Rosenthal KL
J Virol; 2005 Jan; 79(1):393-400. PubMed ID: 15596832
[TBL] [Abstract][Full Text] [Related]
3. Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.
Zurawski G; Shen X; Zurawski S; Tomaras GD; Montefiori DC; Roederer M; Ferrari G; Lacabaratz C; Klucar P; Wang Z; Foulds KE; Kao SF; Yu X; Sato A; Yates NL; LaBranche C; Stanfield-Oakley S; Kibler K; Jacobs B; Salazar A; Self S; Fulp W; Gottardo R; Galmin L; Weiss D; Cristillo A; Pantaleo G; Levy Y
J Virol; 2017 May; 91(9):. PubMed ID: 28202751
[TBL] [Abstract][Full Text] [Related]
4. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge.
Dumais N; Patrick A; Moss RB; Davis HL; Rosenthal KL
J Infect Dis; 2002 Oct; 186(8):1098-105. PubMed ID: 12355360
[TBL] [Abstract][Full Text] [Related]
5. Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations.
Cristillo AD; Ferrari MG; Hudacik L; Lewis B; Galmin L; Bowen B; Thompson D; Petrovsky N; Markham P; Pal R
J Gen Virol; 2011 Jan; 92(Pt 1):128-40. PubMed ID: 21169215
[TBL] [Abstract][Full Text] [Related]
6. CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization.
Sundling C; Schön K; Mörner A; Forsell MNE; Wyatt RT; Thorstensson R; Hedestam GBK; Lycke NY
J Gen Virol; 2008 Dec; 89(Pt 12):2954-2964. PubMed ID: 19008380
[TBL] [Abstract][Full Text] [Related]
7. TLR4 and TLR7/8 Adjuvant Combinations Generate Different Vaccine Antigen-Specific Immune Outcomes in Minipigs when Administered via the ID or IN Routes.
McKay PF; King DF; Mann JF; Barinaga G; Carter D; Shattock RJ
PLoS One; 2016; 11(2):e0148984. PubMed ID: 26862758
[TBL] [Abstract][Full Text] [Related]
8. Nasal vaccination with CpG oligodeoxynucleotide induces protective immunity against non-typeable Haemophilus influenzae in the nasopharynx.
Abe N; Kodama S; Hirano T; Eto M; Suzuki M
Laryngoscope; 2006 Mar; 116(3):407-12. PubMed ID: 16540899
[TBL] [Abstract][Full Text] [Related]
9. Primate immune responses to HIV-1 Env formulated in the saponin-based adjuvant AbISCO-100 in the presence or absence of TLR9 co-stimulation.
Martinez P; Sundling C; O'Dell S; Mascola JR; Wyatt RT; Karlsson Hedestam GB
Sci Rep; 2015 Mar; 5():8925. PubMed ID: 25762407
[TBL] [Abstract][Full Text] [Related]
10. Vaccine induction of antibodies and tissue-resident CD8+ T cells enhances protection against mucosal SHIV-infection in young macaques.
Petitdemange C; Kasturi SP; Kozlowski PA; Nabi R; Quarnstrom CF; Reddy PBJ; Derdeyn CA; Spicer LM; Patel P; Legere T; Kovalenkov YO; Labranche CC; Villinger F; Tomai M; Vasilakos J; Haynes B; Kang CY; Gibbs JS; Yewdell JW; Barouch D; Wrammert J; Montefiori D; Hunter E; Amara RR; Masopust D; Pulendran B
JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830870
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of TLR agonists as potential mucosal adjuvants for HIV gp140 and tetanus toxoid in mice.
Buffa V; Klein K; Fischetti L; Shattock RJ
PLoS One; 2012; 7(12):e50529. PubMed ID: 23272062
[TBL] [Abstract][Full Text] [Related]
12. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
Perdiguero B; Gómez CE; Cepeda V; Sánchez-Sampedro L; García-Arriaza J; Mejías-Pérez E; Jiménez V; Sánchez C; Sorzano CÓ; Oliveros JC; Delaloye J; Roger T; Calandra T; Asbach B; Wagner R; Kibler KV; Jacobs BL; Pantaleo G; Esteban M
J Virol; 2015 Jan; 89(2):970-88. PubMed ID: 25355891
[TBL] [Abstract][Full Text] [Related]
13. Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen.
Arias MA; Loxley A; Eatmon C; Van Roey G; Fairhurst D; Mitchnick M; Dash P; Cole T; Wegmann F; Sattentau Q; Shattock R
Vaccine; 2011 Feb; 29(6):1258-69. PubMed ID: 21145913
[TBL] [Abstract][Full Text] [Related]
14. Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses.
Tritel M; Stoddard AM; Flynn BJ; Darrah PA; Wu CY; Wille U; Shah JA; Huang Y; Xu L; Betts MR; Nabel GJ; Seder RA
J Immunol; 2003 Sep; 171(5):2538-47. PubMed ID: 12928404
[TBL] [Abstract][Full Text] [Related]
15. Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteins.
Albu DI; Jones-Trower A; Woron AM; Stellrecht K; Broder CC; Metzger DW
J Virol; 2003 May; 77(10):5589-97. PubMed ID: 12719551
[TBL] [Abstract][Full Text] [Related]
16. Clade C HIV-1 Envelope Vaccination Regimens Differ in Their Ability To Elicit Antibodies with Moderate Neutralization Breadth against Genetically Diverse Tier 2 HIV-1 Envelope Variants.
Burton S; Spicer LM; Charles TP; Gangadhara S; Reddy PBJ; Styles TM; Velu V; Kasturi SP; Legere T; Hunter E; Pulendran B; Amara R; Hraber P; Derdeyn CA
J Virol; 2019 Apr; 93(7):. PubMed ID: 30651354
[TBL] [Abstract][Full Text] [Related]
17. Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.
Shen X; Bogers WM; Yates NL; Ferrari G; Dey AK; Williams WT; Jaeger FH; Wiehe K; Sawant S; Alam SM; LaBranche CC; Montefiori DC; Martin L; Srivastava I; Heeney J; Barnett SW; Tomaras GD
J Virol; 2017 Oct; 91(19):. PubMed ID: 28490585
[TBL] [Abstract][Full Text] [Related]
18. Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules.
Mercier GT; Nehete PN; Passeri MF; Nehete BN; Weaver EA; Templeton NS; Schluns K; Buchl SS; Sastry KJ; Barry MA
Vaccine; 2007 Dec; 25(52):8687-701. PubMed ID: 18063450
[TBL] [Abstract][Full Text] [Related]
19. CCL19 and CCL28 augment mucosal and systemic immune responses to HIV-1 gp140 by mobilizing responsive immunocytes into secondary lymph nodes and mucosal tissue.
Hu K; Luo S; Tong L; Huang X; Jin W; Huang W; Du T; Yan Y; He S; Griffin GE; Shattock RJ; Hu Q
J Immunol; 2013 Aug; 191(4):1935-47. PubMed ID: 23858028
[TBL] [Abstract][Full Text] [Related]
20. Robust antigen-specific humoral immune responses to sublingually delivered adenoviral vectors encoding HIV-1 Env: association with mucoadhesion and efficient penetration of the sublingual barrier.
Domm W; Brooks L; Chung HL; Feng C; Bowers WJ; Watson G; McGrath JL; Dewhurst S
Vaccine; 2011 Sep; 29(40):7080-9. PubMed ID: 21801777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
